IOncology

In the treatment of low rectal cancer, the “watch and wait” strategy has sparked a compelling debate between organ preservation and radical resection. With the advancement of neoadjuvant therapies, some patients achieve clinical complete response (cCR) following chemoradiotherapy, opening the door to non-operative management and the possibility of avoiding a permanent stoma. However, concerns over local regrowth, subjective response assessment, and the psychological burden on patients continue to challenge the broader application of this approach.

From March 12 to 14, 2025, the 97th Annual Meeting of the Japanese Gastric Cancer Association (JGCA 2025) was held at the Nagoya Congress Center, bringing together leading experts from Japan and across the globe to exchange insights on the latest advancements in gastric cancer prevention and treatment. The event also spotlighted the application and future potential of digital innovations in the field.

At the recently concluded 97th Annual Meeting of the Japanese Gastric Cancer Association (JGCA) in Nagoya, Japan, the team from The Affiliated Hospital of Qingdao University, led by Professor Yanbing…

From February 28 to March 1, 2025, the 9th Annual Meeting of the Chinese Medical Doctor Association Colorectal Oncology Committee was held in Beijing. This year’s meeting focused on the standardization, precision, and personalization of colorectal cancer diagnosis and treatment, drawing top experts from China and around the world to explore the latest advances in the field.

At the recently concluded 97th Annual Meeting of the Japanese Gastric Cancer Association (JGCA 2025) in Nagoya, the surgical oncology team from The Affiliated Hospital of Qingdao University , led…

From March 12 to March 14, 2025, the 97th Annual Meeting of the Japanese Gastric Cancer Association (JGCA) was held in Nagoya, Japan. The event brought together leading gastric cancer…

On March 2025, The Lancet Oncology published results from the UCBG 3-06 START phase 2 trial, comparing darolutamide and capecitabine in patients with triple-negative, androgen receptor-positive (AR+) advanced breast cancer.Although…

A decade after the start of the ShortHER trial, new data published in JAMA Oncology sheds light on how tumor-infiltrating lymphocytes (TILs) can guide treatment decisions in early ERBB2-positive (HER2+)…

In a landmark phase 3 trial published in Nature Medicine, Prof. Sherene Loi and colleagues investigated whether immunotherapy can shift the treatment paradigm in high-risk early ER+/HER2− breast cancer.The study…

As lung cancer diagnosis and treatment enter an era of precision and personalization, Chinese researchers are playing an increasingly pivotal role on the international stage through innovation and collaboration. In this special edition of the Mok Talk interview series, hosted by the talented Professor Yang Xia of The Second Affiliated Hospital of Zhejiang University School of Medicine, we are honored to present a conversation with world-renowned lung cancer expert Professor Tony Mok from The Chinese University of Hong Kong. Joining him are prominent early-career scholars such as Professor Wenhua Liang (The First Affiliated Hospital of Guangzhou Medical University) and Professor Yongchang Zhang (Hunan Cancer Hospital). Together, they discuss academic growth, clinical trial design, and the global impact of Chinese innovations—offering a meaningful intergenerational exchange of ideas.